Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Temozolomide for Recurrent Brain Metastases
NCT00362817Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Oct 2004
- Primary completion
- Jan 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and temozolomide in brain metastases, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Response Rate at 1 year. Started Oct 2004; status: completed.
02
Drugs
carboplatintemozolomide
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT00362817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362817.